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body radiation therapy
without grade 3 acute
toxicity. Stereotactic body
radiation therapy increased
antigen-specific immune re-
sponses in a subset of
patients.determine the recommended phase 1b dose in a “3 þ 3” cohort-based, dose-escalation
design. The primary endpoint was dose-limiting toxicities defined as grade 3 gastro-
intestinal (GI) or genitourinary (GU) toxicity (or both) by National Cancer Institute
Common Terminology Criteria for Adverse Events (version 4) up to 90 days after
the first radiation fraction. The secondary endpoints were prostate-specific antigen ki-
netics, quality of life (QoL), and blood immunologic responses.
Results: Nine patients were treated in phase 1a. No dose-limiting toxicities were
observed at either level, and therefore the maximum tolerated dose was not reached.
Further characterization of tolerability, efficacy, and immunologic outcomes was con-
ducted in the subsequent 11 patients irradiated at the highest dose level (50 Gy) in the
phase 1b expansion cohort. Toxicity was 45% and 25% for grades 1 and 2 GU, and
20% and 5% for grades 1 and 2 GI, respectively. No grade 3 or worse toxicity was
reported. The average (standard error of the mean) of the QoL assessments at base-
line and at 3-month posttreatment were 0.8 (0.8) and 3.5 (1.5) for the bowel (mean
difference, 2.7; 95% confidence interval, 0.1-5), and 6.4 (0.8) and 7.27 (0.9) for the
International Prostate Symptom Score (mean difference, 0.87; 95% confidence inter-
val, 0.3-1.9), respectively. A subset of patients developed antigen-specific immune re-
sponses against prostate-specific membrane antigen (n Z 2), prostatic acid
phosphatase (nZ 1), prostate stem cell antigen (nZ 4), and prostate-specific antigen
(n Z 2).
Conclusions: Irradiation of the whole prostate with 36.25 Gy in 5 fractions and dose
escalation to 50 Gy to the DIN was tolerable and determined as the recommended
phase 1b dose. This treatment has promising antitumor activity, which will be
confirmed by the ongoing phase 2 part. Preliminary QoL analysis showed minimal
impact in GU, GI, and sexual domains. Stereotactic irradiation induced antigen-
specific immune responses in a subset of patients.  2018 The Authors. Published
by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
In 2016, more than 241,000 US men received a diagnosis of
prostate cancer (PCa), approximately 90% of whom had
localized disease.1
Standard treatment options include surgery, radiation
(with or without androgen deprivation therapy [ADT]), and
active surveillance.2 For external beam radiation therapy
(EBRT), dose escalation is known to improve tumor con-
trol,3,4 albeit not without increased toxicity because of the
proximity of organs at risk (OARs), particularly the bladder
and rectum.5
Several studies have suggested that PCa has a low alpha-
to-beta ratio (1.4-2 Gy) that is similar to normal tissue late
effects, suggesting that larger doses per fraction (hypo-
fractionation) would be beneficial to increasing the thera-
peutic ratio.6 Stereotactic body radiation therapy (SBRT) is
a promising technique that allows the use of extreme
hypofractionation to treat localized PCa by using 36.25 Gy
administered in 5 fractions (7.25 Gy per fraction). Results
from both retrospective and prospective series have shown
excellent biochemical outcomes and acceptable toxicity
profiles in patients with low- and intermediate-risk disease,
which serves to reaffirm the concept of a low alpha-to-beta
ratio for PCa.7Studies of patterns of failure after conventional EBRT
have shown that the main site of tumor recurrencedin
more than 90% of casesdwas the dominant intraprostatic
nodule (DIN).8,9
The DIN is defined as the largest nodule that harbors
the most aggressive biological behavior and therefore
dictates the overall clinical prognosis of mutifocal PCa in
a multifocal disease.10 State-of-the-art imaging allows
reliable identification of DINs.11 Indeed, multiparametric
magnetic resonance imaging (mpMRI), using T1- and T2-
weighted sequences, dynamic contrast enhancement to
assess perfusion, and diffusion-weighted imaging to
calculate the different diffusion capability of PCa versus
normal tissues, has markedly improved the sensitivity and
specificity of magnetic resonance imaging (MRI) to detect
and characterize prostatic carcinomas.12 This approach
enables high-precision targeting of DINs and escalation of
the dose of radiation therapy (RT) to the MRI-visible
dominant nodule, which should increase biochemical con-
trol while avoiding the increase in side effects seen with
whole-gland SBRT dose escalation.
Previous landmark trials of dose escalation to the whole
prostate using 45 Gy and 47.5 Gy have shown no evidence
of severe toxicity.13,14 However, further whole-prostate
dose escalation up to 50 Gy has led to an increase in
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support the use of dose escalation to the whole prostate at
least for the first 2 dose levels studied, questions remain
regarding the feasibility and safety of heterogeneous dose-
escalated SBRT delivered to the DIN, particularly consid-
ering the difficulties in manipulating hot spots located in
proximity to healthy organs (urethra, bladder, and rectum).
We therefore performed this SBRT regimen in the context
of a dose-escalated phase 1 study.
We proposed irradiating the whole prostate gland, which
may contain multifocal cancers, with tumoricidal doses of
36.25 Gy in 5 fractions while simultaneously escalating the
dose specifically to the DINs to up to 50 Gy by using
heterogeneous dose distribution (prescription isodose line
80%). We postulated that this approach would increase
local tumor control while reducing genitourinary (GU) and
rectal side effects in patients with intermediate- to high-risk
PCa. Here, we report the results of a phase 1a/b study
investigating boosting DINs by using SBRT while pro-
tecting the rectum, the bladder, and the urethra from high
doses of radiation. To maximize protection of the rectum,
we also used a rectal spacer.
Although the proposed extreme hypofractionated RT
approach was expected to provide excellent local control of
the primary PCa lesion(s), a proportion of patients with
intermediate- or high-risk disease may have recurrences
with distant metastases in the future, requiring strategies to
minimize systemic disease. Hypofractionated EBRT is
known to trigger occasional abscopal effects, meaning the
eradication of a nonirradiated distant metastasis, which is
thought to be mediated largely by adaptive immunity,
specifically T cells.16 Indeed, the triggering of antitumor
immune response by RT has been reported before, but the
optimal dose and schedule of fractionation to maximize
immune effects are not entirely understood and are pres-
ently being debated.16 To better understand the immune
effects of the extreme hypofractionated RT applied, we also
investigated the T-cell responses to PCa-specific antigens in
these patients at different time points before, during, and
after SBRT.Methods and Materials
This phase 1 dose-escalation study was approved by the
Ethics Committee of the Canton Vaud (ClinicalTrials.gov
ID: NCT02254746). Informed consent was obtained from
all patients. The primary endpoint of the study was to
assess acute (up to 90 days after the first RT fraction) uri-
nary and rectal toxicity. Secondary endpoints were prostate-
specific antigen (PSA) kinetics, quality of life (QoL), and
immunologic response to SBRT. Patients were enrolled
from October 2014 to April 2017.
Eligible patients were those with newly diagnosed and
previously untreated PCa, intermediate- and high-risk dis-
ease according to the D’Amico risk classification,17 and
stage T2 to T3 adenocarcinoma of the prostate, N0, M0. Allpatients had to have at least 1 visible nodule at the endor-
ectal coil (ERC) mpMRI. The serum PSA level was
required to be < 50 mg/L, and the International Prostate
Symptom Score (IPSS) 15 (alpha blockers allowed). Pa-
tients were excluded if they had a pre-SBRT prostate vol-
ume on MRI greater than 70 cm3 or a tumor located at less
than 3 mm from the urethra when measured at the ERC
MRI. They were also excluded if they had evidence of
inflammatory colitis or previous RT in the pelvis.
Concomitant or adjuvant ADT was allowed, but neo-
adjuvant ADT was an exclusion criterion.
The Ethics Committee of the Canton Vaud approved the
translational research part of the study, and an independent
informed consent was obtained from patients. Blood was
collected at the following time points: SBRT-0 (day 0 of
SBRT, before the introduction of a rectal spacer), SBRT-5
(the day the patient received the fifth fraction of SBRT),
SBRT-15 (15 days after the last fraction of SBRT), and
SBRT-40 (40 days after the last fraction of SBRT). Patients
with human leukocyte antigen (HLA) allele A2þ were
included in the translational analyses. Exclusion criteria
from the translational analyses were anemia (hemoglobin
<100 g/dL at baseline), human immunodeficiency virus
seropositivity with or without hepatitis B and C active
infection, or any other condition, such as autoimmune
diseases or medication that could have affected the results
of the immune monitoring.Radiation therapy planning and delivery
Approximately 8 to 10 days before the RT scanner simu-
lation, a biodegradable spacer device (BioProtect Balloon,
Ltd., Kfar Saba, Israel) was transperineally inserted be-
tween the prostate and the rectum under transrectal ultra-
sound guidance after the patient received sedative
anesthetics. During the same procedure, 4 fiducial markers
consisting of gold anchors (Gold Anchor, Naslund AB,
Sweden) were placed in the prostate with at least 2 cm of
separation among them to accommodate the fiducial
spacing threshold of at least 1 cm of separation on
orthogonal imaging to ensure accurate rotational correc-
tions. All angles formed by at least 3 fiducials had to be
greater than 15 to comply with the colinearity threshold.18
MRI and computed tomography (CT) scans for treatment
planning were performed 7 days after fiducial implantation
to ensure adequate fiducial marker positioning and to allow
for resolution of edema/inflammation.18 The planning MRI
was immediately followed (after <2 hours) by a planning
CT scan to minimize anatomic changes in the rectum that
may interfere with image fusion. Both planning MRI and
planning CT were performed with the same slide thickness
(1 mm) to favor correct fusion.
Precautions were taken to minimize prostate motion
during the planning scans and treatment. Specifically,
starting 5 days before acquisition of the planning scans
until the end of treatment, patients maintained a low-fiber
Volume 103  Number 2  2019 Prostate SBRT and immunologic responses 323diet to reduce intestinal gas. They were instructed to use a
mild laxative 48 hours before the planning CT scan. When
necessary, enemas were performed 1 hour before acquisi-
tion of the planning scans and before each treatment session
to minimize rectal volume. Patients were also instructed to
drink 200 mL of water 1 hour before the scans, after
voiding completely. All patients had images taken and were
treated in the supine treatment position with a knee cushion
to maximize patient comfort and limit prostate motion in
response to respiration.19
For accuracy on contouring and appropriate visualiza-
tion of the DIN and OARs, the planning T2-weighted MRI
image sets after rectal spacer/fiducial markers insertion
were rigidly fused to the planning-CT images using Ve-
locity Advanced Imaging Software (Varian Medical Sys-
tems, Palo Alto, CA). Intraprostatic fiducials were used to
guide image coregistration and limit fusion errors.20 Axial
and sagittal planes of both planning MRI and planning CT
scans were used to maximize the visualization of the fi-
ducials and guide coregistration.
The diagnostic ERC mpMRI performed before rectal
spacer and fiducial marker insertion was deformably
coregistered to the planning MRI and the planning CT
scans to aid in accurate localization of the target volume
and OARs.21 This process was performed with Velocity
Advanced Image Software (Varian Medical Systems, Palo
Alto, CA) using the fade correction algorithm.
Anatomical contours of the prostate, DIN, seminal ves-
icles, and OARs were performed on the planning-CT scan
by the principal investigators of the trial (FH and JB) before
being scrutinized by a panel of board-certified radiation
oncologists. A radiologist (J-YM) delineated the DIN as the
region of interest in the MRI. The prostate was expanded
uniformly by 3 mm to create the planning target volume
(PTVp).
The DIN was contoured as the gross tumor volume and
expanded by 3 mm to create a PTVDIN (no clinical target
volume was used around the gross tumor volume). The
prescribed dose to the PTVp was 36.25 Gy in 5 fractions
(7.25 Gy per fraction). The prescribed dose to the PTVDIN
was 45, 47.5, and 50 Gy in 5 fractions, corresponding to the
80% isodose line; therefore the maximum dose point cor-
responded to 56.25, 59.38, and 62.5 Gy, respectively. To
allow gradients for DIN boosting and to maximize PTVDIN
doses, there were no limits on dose heterogeneity. At least
95% of the volume of interest (PTVDIN and PTVp) had to
be covered by >95% of the prescription dose. A minimum
of 2 days and a maximum of 6 days had to separate each
treatment fraction. No more than 2 fractions would be
delivered per week. The overall treatment time had to be no
more than 20 days.
We recognize that this treatment is a more conservative
treatment schema than the ones tested in previous trials,
which usually delivered 5 fractions in consecutive days or
every other day. This fractionation schema was based on
that of Fowler et al,22 who advised to prolong the total
treatment time to at least 5 weeks to avoid side effects.From the disease-control perspective, the prostate carci-
noma cell repopulation time was assumed to be 40 days
(range, 15-60 days), and thus the proliferation between
fractions was theoretically negligible.22
Dose-volume histogram goals for the rectum were
maximum dose to 1 cm3 < 38 Gy, maximum dose to
0.1 cm3 < 41 Gy, and V25 < 20 (ie, the volume receiving
25 Gy < 20 cm3). The bladder dose-volume histogram was
limited to no more than 1 cm3 receiving 41 Gy or greater,
0.1 cm3 to receive less than 45 Gy, and the bladder median
dose was not to exceed 20 Gy. The urethra dose was limited
to no more than 1 cm3 of urethra receiving more than 39 Gy
and 0.1 cm3 not to exceed 41 Gy (Fig. 1).
SBRT was delivered via CyberKnife (Accuray Inc,
Sunnyvale, CA) with energies of 6 MV. The CyberKnife
unit is equipped with 2 orthogonal x-ray imaging devices
for automated image guidance based on fiducial markers.
Before treatment delivery, the system determined the ab-
solute position of the fiducial markers via CT image-to-
digitally reconstructed radiograph registration. This method
allowed for the assessment of potential marker migration or
misalignment between fractions (interfraction motion).23,24
During treatment delivery, orthogonal x-ray images were
used to locate the center of mass of implanted gold fiducial
markers within the prostate and allowed for targeting and
correction of the therapeutic beam during an individual
treatment (intrafraction motion). A minimum of 3 properly
placed fiducials was required to accommodate 6-
dimensional tracking. The goals of fiducial tracking were
to keep the translational shifts (X, Y, Z) to less than 2 mm
and the rotational shifts to less than 5 (roll maximum 2,
pitch maximum 5, yaw maximum 3) throughout treat-
ment. Imaging was obtained every 30 to 60 seconds to
assure submillimeter tracking accuracy.
The shift of x-ray images from the planning CT scan
was monitored in real time during each fraction. If the
calculated shift was more than the given threshold, the
treatment would be paused and manual couch movement
would be required until the shift was below the limit. The
implementation of this technique for daily setup and
intrafraction corrections was shown by others to help
decrease the required PTV margins to less than 3 mm.25Treatment schema, definitions, and statistical
analysis
The radiation dose to the whole prostate was 36.25 Gy in 5
fractions of 7.25 Gy. For dose escalation to the DIN, we used
the traditional 3 þ 3 design, which remains the prevailing
method for conductingphase 1 cancer clinical trials; one of its
theoretical main advantages is that it is recognized as being
safe.26 The dose-expansion cohort was used to confirm the
safety of the treatment at the recommended phase 2 dose.27
Patients in the phase 1a part (in cohorts of 3 per dose
level) were treated with a starting dose to the DIN of 9 Gy
per fraction up to 45 Gy. If no DLTwas observed in the first
Fig. 1. Patient with a prostate cancer (T2, N0, M0; Gleason Score, 3 þ 4 Z 7; prostate-specific antigen, 20 mg/L).
Magnetic resonance imaging shows 2 lesions in the medial region, in the right and left posterior peripheral zones, with
hypointensity on axial T2-weighted image (A), restriction of diffusion on apparent diffusion coefficient map (B) and on
diffusion-weighted images (C), and Prostate Imaging Reporting and Data System (4 on the left and 5 on the right). RT
planning magnetic resonance imaging scan shows a hyperintense rectal spacer on the axial (D) and sagittal (E) T2-weighted
images. (F) RT planning was performed on a CT scan, and an axial image shows the RT volumes: prostate in red, tumor in
yellow, rectal spacer in pink, rectum in light blue, and urethra in green. Fiducial markers were placed in the prostate for
robotic-assisted tracking purposes. (G) Stereotactic body radiation therapy plan using CyberKnife. The whole prostate was
treated with 36.25 Gy in 5 fractions of 7.25 Gy (dark-blue isodose) with a boost of 47.5 Gy to the dominant intraprostatic
nodule (orange isodose). (H) Dose-volume histogram shows the maximal dose delivered to the urethra: 0.1 cm3 Z 38 Gy
(light-green curve); the anterior rectal wall, 1 cm3 Z 25.9 Gy (light-blue curve); and the bladder: 1 cm3 Z 38 Gy (yellow
curve). The prostate (red curve) and the tumors (orange curve) received the prescribed dose. Abbreviations: CIZ computed
tomography; RT Z radiation therapy.
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dose level (47.5 Gy in 5 fractions of 9.5 Gy), with dose
escalation continuing until DLT was observed or if the
maximum dose level (50 Gy in 5 fractions of 10 Gy) was
reached in the absence of a DLT. If 1 of the 3 patients
experienced a DLT at a particular dose level, an additional 3
patients were planned to be included at that level. If 2 or
more patients experienced a DLT at a given dose level, a
lower dose level would have been explored to define the
maximum tolerated dose. The 3 patients included in a
cohort could be enrolled simultaneously or sequentially
without any waiting period among them. However, dose
escalation in the phase 1a was not allowed until the last
patient included in a specific cohort completed a minimum
follow-up period of 90 days without experiencing DLT.
DLTs were defined as grade 3 or higher gastrointestinal
(GI) or GU toxicity that appeared from the first fraction of
RT and up to 90 days after completing treatment. Once the
maximal dose level was reached, an interim analysis was to
be conducted per protocol and evaluated by the Indepen-
dent Data and Safety Monitoring Board, with a cutoff date
of April 4, 2015. If this evaluation did not identify any
safety issues, additional patients were to be treated at the
maximal dose level to confirm the safety and tolerability of
the combination in a phase 1b expansion cohort.
All adverse events were graded by the National Cancer
Institute Common Toxicity Criteria, version 4. Secondary
endpoints were late toxicity (occurring >90 days from first
fraction), PSA kinetics, and patient-reported outcome. Eu-
ropean Organisation for Research and Treatment of Cancer
QoL Form PR25 (prostate module) together with the IPSS
score were collected at baseline and 1, 3, and 6, months
after treatment. Health-related QoL outcomes were scored
using the European Organisation for Research and Treat-
ment of Cancer guidelines28 into values ranging from zero
to 100. A difference of 10 points or more was considered
clinically relevant.29 Patients were followed up by having
PSA measurements, a history, and a physical examination
performed every 3 months for the first 2 years, and every
6 months thereafter. The nadir þ2 mg/mL failure definition
was used for biochemical control.30 Analyses were done in
Prism 7 (GraphPad Software, Inc, La Jolla, CA).
Immune monitoring
All analyses were performed after Minimal Information
About T cell Assays (MIATA) guidelines.31 In squared
brackets, the reader can follow the Minimal Information
About T cell Assays modules and submodules submitted as
Appendix E1 (available online at https://doi.org/10.1016/j.
ijrobp.2018.09.023).
Patient material
Peripheral blood mononuclear cells (PBMCs) were isolated
from Li-heparin whole blood with drawls (1.2, 1.3, 1.4) bydensity gradient using Ficoll-Paque Plus (GE Health care),
according to the laboratory standard of practice (1.6, 5.1,
5.4), and immediately cryopreserved in 90% FCS (Fetal
Calf Serum; Gibco) and 10% dimethyl sulfoxide in Cool-
Cells devices (BioCision) at e80 C and transferred after
24 hours in liquid nitrogen until analysis (1.10, 1.11, 1.12).
Cryopreserved PBMCs were thawed in Roswell Park
Memorial Institute (RPMI) medium (Invitrogen), 20%
FCS, and counted with the Trypan Blue method in Neu-
bauer counting chambers (1.20). Viability after thawing
was >85% (1.15). Cells were then split between flow
cytometry analyses (3  10E6) or rested for 5 hours in
RPMI-8% human AB serum (HS; Biowest) at 37C before
the in vitro stimulation.
Analysis of T-cell responses against Human leukocyte
antigen (HLA) serotype A2 (HLA-A2) restricted epitopes of
the PCa-specific antigens prostate stem cell antigen (PSCA),
prostate-specific membrane antigen (PSMA), PSA, and
prostatic acid phosphatase (PAP) were quantified by IFNg
Enzyme-Linked ImmunoSpot (ELISpot). We also performed
enumeration of circulating leukocytes and phenotypic and
functional characterization of T cells.
All assays were performed using general research
investigative assays (5.5).In vitro stimulation of antigen-specific T cells
Given the precursor frequencies of antigen-specific T cells
in peripheral blood samples, a conventional highly sensitive
assay was used to quantify antigen-specific T-cell re-
sponses.32-34 Thawed PBMCs rested for 5 hours in RPMI
(Invitrogen), and 8% human AB serum (HS; Biowest)
supplemented with penicillin or streptomycin and beta-
mercaptoethanol at 37C (2.1) were plated in 96-well
plates at 10E5 cells per well in RPMI-8% human serum.
Peptide pools (see the following list) were added in repli-
cates (2-6 wells per condition). Peptide pools were
composed of the following:
 Prostate stem cell antigen (PSCA7-15 ALLMAGLAL,
PSCA14-22 ALQPGTALL, PSCA21-30 LLCYSCKAQV)
 Prostate-specific membrane antigen (PSMA4-12
LLHETDSAV, PSMA27-38 VLAGGFFLL, PSMA441-450
LLQERGVAYI, PSMA663-671 MMNDQLMFL)
 Prostate-specific antigen (PSA53-61 VLVHPQWVL,
PSA146-154 KLQCVDLHV, PSA165-174 FLTPKKLQCV,
PSA178-187 VISNDVCAQV)
 Prostatic acid phosphatase (PAP18-26 FLFLLFFWL,
PAP112-120 TLMSAMTNL, PAP299-307 ALDVYNGLL)
Recombinant human interleukin-2 was added to the cul-
ture after 48 hours at a final concentration of 100 U/mL
(2.4). At day 12, IFN-g ELISpot assays were performed
using precoated 96-well ELISpot plates (ELISpotPRO kit for
Human IFN-g from Mabtech, ref 3420). Analyses were
performed with an established laboratory protocol and under
Good Laboratory Practice conditions (5.1, 5.4). Each
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fraction was rechallenged with 1 mg/mL of the correspond-
ing peptide pool for 16 to 18 hours at 37C and 5% CO2.
As a positive control, 5  10E4 cells stimulated with
staphylococcal enterotoxin B at a concentration of 0.25 ng/
mL or respective cells without rechallenge (medium only)
were used as negative control (2.5). Plates were washed
according to the manufacturer’s instructions and counted
with the iSpot Robot ELISpot reader (AutoImmun Diag-
nostika GmbH).
For each condition, background was subtracted from
each replicate (unstimulated fraction was considered as a
negative control), and the relative magnitude of tumor-
specific T-cell responses was determined for each antigen,
time point, and patient as the proportion of positive repli-
cates (ie, see the background described in the preceding
paragraphs [3.4, 4.4]) of the total number of replicates
tested (4.6). The relative magnitude of prostate cancer
antigen-specific T-cell responses ranged from 0 to 1, cor-
responding to the proportion of positive replicates. The
cumulative prostate antigen T-cell response was measured
for each patient as the sum of the individual responses
against the 4 distinct prostate cancer antigen peptide pools
and ranged from 0 to 4. Row data of ELISpot assay can be
provided to the reader on request.
Flow cytometry phenotypic analyses
Fresh thawed patient PBMCs were washed and stained in
phosphate-buffered saline with the following distinct panels
(2.1, 2.2):
 PBMC basic phenotype panel: CD3 APC (IM2467, BC),
CD4 PE-Cy7 (737660, BC), CD8 Pacific Blue (558207,
BD), CD14 APC-H7 (641394, BD), CD16 FITC
(555406, BD), CD56 PE (A07788, BC), CD11c Alexa
Fluor 700 (561352, BD), CD19 Brilliant Violet 711
(563036, BD), CD123 PerCP-Cy5.5 (45-1239-42, eBio-
science), HLA-DR ECD (IM3636, BC), Zombie UV
(77474 BioLegend)
 CD8 T-cell panel: CD3 PerCP-Cy5.5 (300430, Bio-
Legend), CD8 Brilliant Violet 650 (301042, BioLegend),
CD45RA Alexa Fluor7 00 (560673, BD), CCR7 (CD197)
Brilliant Violet 711 (353228, BioLegend), CD127 Bril-
liant Violet 605 (351334, BioLegend), PD1 (CD279)
Brilliant Violet 421 (329920, BioLegend), ICOS
(CD278) APC-eFluor 780 eBioscience (47-9948-42),
CCR4 (CD194) PE-Cy7 (557864, BD), Zombie UV
(77474 BioLegend), Granzyme B PE-Texas Red
(GRB17, Life Technologies), Perforin-PE (AB47226
Abcam), BAX Alexa Fluor 488 (633604, BioLegend),
BCL-2 (658706, BioLegend)
 CD4 Treg panel: CD3 Brilliant UV496 (564809, BB),
CD4 Brilliant Violet 510 (317444, BioLegend), CD45RA
Alexa Fluor 700 (560673, BD), CCR7 (CD197) Brilliant
Violet 711 (353228, BioLegend), CD127 Brilliant Violet
605 (351334, BioLegend), CD25 PE (A07774, BC),ICOS (CD278) APC-eFluor 780 eBioscience (47-9948-
42), CCR4 (CD194) PE-Cy7 (557864, BD), CD73 PE-
Dazzle 594 (344020, BioLegend), CD14 PerCP-Cy 5.5
550787, BD), Zombie UV (77474 BioLegend), FoxP3
eFluor 450 (48-4776-02, eBioscience), BAX Alexa Fluor
488 (633604, BioLegend), BCL-2 (658706, BioLegend)
Staining was performed at 4C in the dark, and for
intracellular staining, the FoxP3 Fix/Perm kit (eBioscience)
was used (2.4). Analyses were performed with an estab-
lished laboratory protocol and under Good Laboratory
Practice conditions [5.1, 5.4].
Samples were acquired on a 5-laser BD LSRFortessa
cytometer equipped with FACSDiva software version 8.0.1
(3.1). Cytometer Setup and Tracking (CS&T) settings were
performed daily and before each experiment (3.2). Ana-
lyses were performed with FlowJo (FLOWJO.LLC) soft-
ware version 10 (3.3, 3.4), and all data were processed in
GraphPad PRISM version 7. FCS files can be provided to
the reader on request (4.3).
Analyses of the T-cell proliferation capacity
Cryopreserved PBMCs were thawed in RPMI (Invitrogen),
20% FBS. After an overnight rest in RPMI (Invitrogen) and
8% human AB-serum (HS; Biowest) supplemented with
penicillin, streptomycin, and beta-mercaptoethanol at 37C
and 5% CO2 (2.1), cells were labeled with 1.5-mM final
concentration Carboxyfluorescein succinimidyl ester (CFSE)
(CellTrace CFSE Cell Proliferation Kit, Life Technologies)
according to the manufacturer’s instructions and laboratory
robust standard operating procedures (5.4) and stimulated
with 50 ng/mL of an anti-CD3 antibody (Mabtech). After
6 days of in vitro expansion, cells were washed and stained
for dead cells (Zombie UV Fixable viability kit, BioLegend)
and with CD3 APC-Fire 750 (344840, BioLegend), CD4
Pacific Blue (558116, BD), and CD8 Brilliant Violet 650
(301042, BioLegend). The percentage of proliferated
CFSElow cells and CD4þ and CD8þ T cells was determined
among viable T cells (4.4). A representative data set is
shown in Figure E3D-E; available online at https://doi.org/
10.1016/j.ijrobp.2018.09.023 (3.4]). As negative control,
nonstimulated cells were used (2.5). FCS files for all samples
can be provided on request (4.3).Results
Early PSA kinetics, side effects, and patient-
reported outcomes
A total of 20 patients were treated and are evaluable for
study endpoints (9 patients in phase 1a and 11 patients in
phase 1b). Patients’ pathologic and treatment characteris-
tics are detailed in Table 1. The median age was 73.5 years
(range, 58-85 years). The PSA was 12.3 (range, 2.7-40 mg/
mL), the IPSS was 7 (range, 0-12), and the prostate volume
Table 1 Patient characteristics
Characteristics
Number of patients
(N Z 20)
Patients
(%)
Tumor stage
T2a 6 30
T2b 6 30
T2c 5 25
T3a 3 15
Gleason Score
3 þ 3 2 10
3 þ 4 8 40
4 þ 3 5 25
4 þ 4 2 10
3 þ 5 1 5
4 þ 5 2 10
Intermediate-risk*
(Gleason Score Z 7 or PSA
10-20, T2b)
7 35
High-risk*
(Gleason Score 8 or
PSA >20 or T2c)
13 65
Hormone therapy
Yes 1 5
No 19 95
Abbreviations: PSA Z prostate-specific antigen.
* Risk stratification according to D’Amico classification.17
Table 2 Genitourinary and gastrointestinal toxicity accord-
ing to grade and time
Grade
Genitourinary toxicity
Gastrointestinal
toxicity
90 d >90 d 90 d >90 d
N % N % N % N %
1 9 45 6 30 4 20 1 5
2 5 25 2 10 1 5 0 0
Abbreviations: NZ number of patients having developed grade 1 or
2 toxicity.
Toxicity graded according to Common Terminology Criteria of
Adverse Events, version 4.
No grade 3 or higher toxicity was reported. Period: from day 1 of
stereotactic radiation therapy and up to 90 days after the first fraction
or more than 90 days after the first radiation fraction.
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number of DINs treated was 2 (range, 1-3), and the median
DIN volume was 2 cm3 (range, 0.6-4). Sixty-five percent of
the patients were high risk, and 35% were intermediate risk,
according to the D’Amico classification.17 The median RT
treatment duration was 19 days (range, 14-19 days). All
patients were able to complete their treatments. None of the
patients died or were unavailable for follow-up. Despite
ADT being offered to the entire patient population, only 1
intermediate-risk patient accepted to undergo 6 months of
ADT.
No DLT was observed within 90 days from the start of
treatment, and thus dose escalation proceeded through all
planned dose levels. Consequently, 3 patients were entered
in each dose level (NZ 9), and 11 additional patients were
enrolled at the 50-Gy dose level (N total Z 20).
The number of patients experiencing GI and GU toxicity
by grade and time is shown in Table 2. Table E1 (available
online at https://doi.org/10.1016/j.ijrobp.2018.09.023)
shows the most common reported acute adverse events.
Only grade 1 and 2 GI and GU toxicity was observed
within 90 days. The most common early GU toxicity was
urinary frequency and urgency. No grade 3 toxicity
occurred over the complete course of follow-up in any of
the dose levels. No complications or side effects were
observed because of the placement of the rectal spacer.
With a median follow-up of 24 months (range, 6-
39 months), 19 of 20 men showed a marked reduction in
early PSA measurements. Figure E1A (available online
at https://doi.org/10.1016/j.ijrobp.2018.09.023) shows thedecline in PSA as a function of patients’ initial PSA. One
patient experienced a biochemical failure 1 year after
treatment; he had a baseline of cT3a, N0, M0 and a Gleason
Score of 9 disease; he was ultimately found to have distant
metastases without evidence of recurrence in the prostate.
All of the patients completed the patient-reported
outcome questionnaires at 4 time points. Figure E1 B-E
(available online at https://doi.org/10.1016/j.ijrobp.2018.
09.023) shows trends in (B) PR-25 change in urinary
function, (C) IPSS scores, (D) PR-25 bowel symptoms
scores, and (E) PR-25 sexual activity scores.
The average (standard error of the mean) of the QoL
assessments at baseline and at 3 months posttreatment for
all patients was 0.8 (0.8) and 3.5 (1.5), respectively, for
PR25 bowel module (mean difference, 2.7; 95% confidence
interval [CI], 0.1-5); 11 (2.8) and 18 (3.3) for the PR25
GU module (mean difference, 7; 95% CI, 3.3-10); 6.4
(0.8) and 7.27 (0.9) for IPSS (mean difference, 0.87;
95% CI, 0.3-1.9); and 42.4 (7.25) and 36.3 (7.41) for
PR25 sexual activity module (mean difference, 6; 95% CI,
0.09-12).
Tables 3 and 4 show the planned versus the delivered
doses to the targets and OARs.Immunologic monitoring
We measured peripheral blood leukocyte subsets longitu-
dinally in 8 of 20 HLA-A2þ patients treated in this phase 1
study. We found no radiation-induced decline in peripheral
blood leukocyte populations including natural killer cells;
CD3þ, CD4þ, and CD8þ T cells; CD4þ-to-CD8þ ratio;
CD19þ B cells; and dendritic cells and monocytes up to
40 days after treatment (Fig. 2A-D). Analysis of absolute
cell counts confirmed this observation (Fig. E2 A-B;
available online at https://doi.org/10.1016/j.ijrobp.2018.09.
023). We did not observe variations in lymphocyte pheno-
type during or after treatment (Fig. E2 C-D; available online
at https://doi.org/10.1016/j.ijrobp.2018.09.023). The overall
Table 3 Dosimetry analysis for the organs at risk
Organ
at risk
Dose planned per
protocol Median delivered (range)
Rectum 0.1 cm3 <41 Gy 0.1 cm3 <33 Gy (26-41 Gy)
1 cm3 <38 Gy 1 cm3 <27 Gy (24-36 Gy)
V25 Gy <20 cm3 V25 Gy 3 cm3 (0.6-20 cm3)
Bladder 0.1 cm3 <45 Gy 38 Gy (37.5-41 Gy)
1 cm3 <41 Gy 37 Gy (36-39.5 Gy)
Median dose <20 Gy 14.16 (4-20 Gy)
Urethra 0.1 cm3 <41 Gy 38 Gy (35-41 Gy)
1 cm3 <39 Gy 36.33 Gy (33.4-39 Gy)
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upon T cell receptor (TCR) stimulation also remained unaf-
fected by the treatment (Fig. E3A-C; available
online at https://doi.org/10.1016/j.ijrobp.2018.09.023), and
the viability of T cells expanded ex vivo and in vitro
remained stable before and after treatment (Fig. E3D; avail-
able online at https://doi.org/10.1016/j.ijrobp.2018.09.023).
Next, we assessed whether radiation induced T-cell re-
sponses against PCa antigens, including PSMA, PSA,
PSCA, and PAP. To this end, we stimulated peripheral CD8
purified T cells with pools of peptides derived from prostate
cancer antigens for 12 days in vitro and then rechallenged
expanded T cells with the same cognate antigens to deter-
mine the relative magnitude of tumor antigen-specific CD8
T-cell responses, as recently described.34 We detected a
prostate cancer antigenespecific immune response after
treatment in 5 of 8 patients. We detected radiation-induced
T-cell responses directed against PSCA in 4 patients, PSA
in 2 patients, PSMA in 2 patients, and PAP in 1 patient.
Responses were observed as early as 15 days after the end
of SBRT and persisted on day 40 after the end of treatment
(for PSCA, n Z 4 patients, and for PSMA, n Z 1 patient;
Fig. 3A). A significant increase in the overall magnitude of
tumor antigenespecific T-cell responses was observed
40 days after the end of treatment relative to the pretreat-
ment baseline (P Z .014; Fig. 3B). The responses against
PAP and PSA were generally transient and substantially
lower in magnitude compared with the PSCA-specific re-
sponses. We did not observe any correlation between
peptide-specific immunoreactivity and clinical outcome
because the 8 patients participating in the translational part
had a decline in PSA measurements.Table 4 Dosimetry analysis for targeted volumes
Target volume
Median dose Gy
(ranges)
Minimum dose Gy
(ranges)
Maximum
(ran
PTVDIN phase 1a 50 (47-55) 41 (34-44) 56.5 (5
PTVDIN phase 1b 53 (50-57) 43 (32-48) 60 (5
PTVp 40 (37-42) 31 (27-35) 57 (4
Abbreviations: NA Z not applicable; PTVDIN Z planning target volume o
the prostate.Discussion
The essential goal of PCa RT is to administer a risk-
adjusted and patient-tailored treatment offering maximal
cancer control and minimal side effects. We demonstrate
the feasibility of dose escalation to the DINs to up to 50 Gy
in 5 fractions, without grade 3 or higher acute urinary and
rectal toxicity. However, in our study, 70% of the patients
experienced acute grade 1 or 2 urinary toxicity that per-
sisted at more than 90 days in 40% of them. It is difficult to
ascertain whether these grade 1 or 2 symptoms will persist
or worsen with longer follow-up.
Reported rates of acute grade 1 or 2 GU toxicity in
previous SBRT trials were between 28% and 78%.35-40
Most of these SBRT series limited PTV doses to 35 to
36.25Gy in 5 fractions.35-40 Series using heterogeneous
dose distribution to 50 Gy using CyberKnife have reported
grade 1 to 2 acute GU toxicities of 50% to 60%.41,42
A recent study using high-dose-rate brachytherapy to
deliver a boost (18.75 Gy in 1 fraction) to the DIN
after SBRT (37.5 Gy in 15 fractions) reported 20% acute
grade 2 GU toxicity that persisted in 6.7% of the patients.43
In a multicenter dose-escalation phase 1-2 SBRT study in
patients treated to 50Gy in 5 fractions, Boike et al13
reported a grade 1 to 2 acute GU toxicity of 60%. Simi-
larly, Quon et al reported an acute grade 1 to 2 GU
toxicity of 64% when irradiating the whole prostate gland
to 40 Gy in 5 fractions every other day.44 Therefore, the
grade 1 to 2 acute GU toxicity profile reported in our study
is in line with the ones previously reported. We have not
observed acute grade 3 or higher GU toxicity or GI toxicity
in our study. Reported rates of acute grade 3 urinary or
rectal toxicity were between 0% and 7% in previous
trials.13,35-40,44
Previous SBRT studies irradiating the whole prostate
gland with a dose between 35 and 37 Gy have reported
acute grade 1 or 2 GI toxicity rates of 16% to 80%.35-40
Quon et al reported 82% acute grade 1 to 2 GI toxicity
using 40 Gy in 5 fractions to the whole prostate.44 Boike
et al reported 54% acute grade 1 to 2 GI toxicity in the
whole-prostate, 50-Gy dose cohort.13 Gomez-Iturriaga et al
reported 13% acute grade 1 to 2 GI toxicity using high-
dose-rate brachytherapy to the DIN.43 We have observed
a 25% incidence of acute grade 1 to 2 GI toxicity that
persisted at more than 90 days in 5% of the patients. Thisdose Gy
ges)
Median D95 Gy
(ranges)
V36.25 cm3
(ranges)
V50 cm3
(ranges)
0-62) 45 (40-50.4) NA 4 (2-6)
4-63) 48 (40-51.3) NA 3.2 (0.5-6.7)
5-62.5) 36 (35-37.6) 76.7 (47-101) NA
f the dominant intraprostatic nodule; PTVpZ planning target volume of
A B
C D
Monocytes populations
total monocytes classical intermediate non-classical
100
100100
80
8080
Pe
rc
en
ta
ge
 o
f 
ce
lls
Pe
rc
en
ta
ge
 o
f 
ce
lls
CD56dim CD56hi mDC pDC B cells
NK cells DC
Pe
rc
en
ta
ge
 o
f 
ce
lls
P = NS
P = NS
P = NS
P = NS
P = NS
P = NS
P = NS
P = NS
P = NS
P = NS
P = NS
SBRT-0
SBRT-0SBRT-0
SBRT-5
SBRT-5
SBRT-5
SBRT-15
SBRT-15
SBRT-15
SBRT-40
SBRT-40
SBRT-40
CD3+ CD4+
Populations
CD8+
60
6060
40
4040
20
2020
0
00
SS
C
SS
C
SS
C
CD
19
CD
4
CD
11
c
CD
16
CD14
A
B
C
E
F
G
H
I
J
K
L
M
N
O
R
Q
P
CD16 CD123
CD8CD3Live/ Dead FSC
HLA-DR
CD
56
Fig. 2. Longitudinal analyses of peripheral lymphocyte subpopulations: (A) Flow cytometry gating strategy of a patient’s
peripheral blood mononuclear cells. The gating strategy involved first identifying the lymphocyte population by forward
scatter and side scatter. Nonviable cells were gated out (A and B), and then B cells (CD19þ) were separated (F) from all other
cell populations. Viable T cells (CD3þ) were selected (E), and then the 2 main types of T cells were defined by CD4þ
(T-helper cells; H) and CD8þ (cytotoxic T cells; I). Classical (P), intermediate (Q), and nonclassical monocyte (R) populations
were gated based on their forward scatter and side scatter characteristics (C) and CD14 and CD16 expression. By using CD16
and CD56, natural killer cells were identified in the CD2-negative population (G) and subdivided to give the 2 main types:
CD56highCD16e (J) and CD56dimCD16þ (K) cells. mDC - N and pDC - O were gated based on the positive expression of
HLA-DR (M) and were stained for expression of CD11c and CD123. HLA-DRþ populations that are CD11cþ and CD123lo
are considered to be mDCs; those that are CD11c and CD123hi are considered to be pDCs. (B) Percentages of CD3þ, CD4þ,
and CD8þ T cells over the study period. (C) Percentages of total monocytes (CD14þ), composed of classical (CD14þ),
intermediate (CD14dimCD16þ), and nonclassical (CD14CD16þ) monocytes over the study period. (D) Percentages of
natural killer cells (CD56dim, left, andCD56high, right), dendritic cells (mDC [HLA-DRþ CD11cþ CD123] and pDC [HLA-
DRþCD11ceCD123þ]) gated on CD3e cells and B cells (CD19þ) over the study period. Abbreviations: HLA Z human
leukocyte antigen; mDC Z myeloid dendritic cells; NS Z not significant; pDC Z plasmacytoid dendritic cells;
SBRT Z stereotactic body radiation therapy; SBRT-0 Z day 0 of SBRT; SBRT-5 Z day 5 of SBRT; SBRT-15 Z 15 days
after completing SBRT; SBRT-40 Z 40 days after completing SBRT.
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using SBRT 40 to 50 Gy to the whole gland in 5 fractions.
It may be due in part to the incorporation of a mandatory
rectal spacer to create a distance of several millimeters
between the rectal wall and the DIN. We thus were able to
keep our dose limits below the rectal dose limits previouslyreported by Kim et al as being predictors of rectal toxicity
(>3 cm3 of the anterior rectal wall exposed to 50 Gy or
>35% of the rectal wall circumference exposed to
39 Gy).14
Longer follow-up is required in our study to evaluate
late radiation-induced toxicity, which can occur even
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Fig. 3. (A) Longitudinal analyses of the relative magni-
tude of prostate antigenespecific T-cell responses. Heat-
maps represent relative magnitude of antigen-specific T-cell
responses measured by IFN-g ELISpot against the 4
distinct peptide pools derived from PSCA, PSMA, PSA,
and PAP. The relative magnitude of prostate
antigenespecific T-cell responses was determined, for each
antigen/time point/patient, as the relative proportion of
positive replicates (ie, above internal background) of the
total number of replicates tested. Patients are represented
with alphanumeric codes. (B) Comparison of detection of
prostate antigenespecific T cells in peripheral blood by the
ELISpot assay at baseline (SBRT-0) and at day 40 after
completing SBRT. The cumulative magnitude, ranging
from 0 to 4, corresponds to the sum of relative magnitudes
of tumor antigenespecific T-cell responses shown in (A)
for each of the 4 antigens. A nonparametric Mann-Whitney
U (Wilcoxon) test was used to compare the matched results,
with a P value of < .05 considered statistically significant.
=
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of 309 patients treated with 40 Gy in 5 fractions with a
median follow-up of 61 months, there were 2% grade 3 or
higher late GU toxicities and no grade 3 or higher GI
toxicities.45 Along the same lines, Hannan et al15 reported
the long-term toxicity of 50 Gy in 5 fractions with a median
follow-up of 54 months: late grade 3 urinary and rectal
toxicities was 5.5% and 7%, respectively. This toxicity
appeared with doses greater than 47.5 Gy in 5 fractions
delivered every other day to the whole prostate. When
Quon et al reported the results of 40 Gy in 5 fractions with
a median follow-up of 48 months, late grade 3 toxicity was
1.33% for GI and 6.7% for GU.44
Diminishing GU and GI acute and long-term toxicity
while increasing the therapeutic outcome should be the aim
of SBRT dose-escalation techniques. This approach firmly
relies on the accurate delivery of radiation to the target
volume. Interfraction and intrafraction motion control
guaranteeing that the fiducial position matches the original
position on the planning CT scan is a prerequisite that can
avoid hot spots to coincidently enter in contact with healthy
organs, such as the urethra.
We have made use of fiducial markers in our patients
and have delivered the treatment with CyberKnife.
CyberKnife precisely delivers highly conformal radiation
to the prostate with 6-dimensional correction of intra-
fraction prostate motion.18,46 We have also excluded pa-
tients with tumors located close to the urethra (within
3 mm). In addition, we have incorporated a mandatory
rectal spacer to create a distance of several millimeters
between the rectal wall and the prostate to reduce rectal
toxicity. Longer follow-up is required in our study to
monitor late effects and eventually observe the benefits of
those interventions.
In our study, patient-reported outcomes and clinician-
reported assessments were performed with the aim of being
complementary and to more fully document the burden of
toxicities and subjective symptoms, such as sexual
dysfunction. Nevertheless, we recognize the obvious limi-
tation of our study in performing QoL analysis in a rela-
tively small number of patients, and therefore our results
should be interpreted with caution. Several key studies have
prospectively examined the importance of health-relatedA significant increase in the overall magnitude of tumor
antigenespecific T-cell responses was observed 40 days
after the end of treatment relative to pretreatment baseline
(P Z .014). Abbreviations: IFN-g Z interferon gamma;
PAP Z prostatic acid phosphatase; PSA Z prostate-spe-
cific antigen; PSCA Z prostate stem cell antigen;
PSMA Z prostate-specific membrane antigen;
SBRT Z stereotactic body radiation therapy; SBRT-
0 Z day 0 of SBRT; SBRT-5 Z day 5 of SBRT; SBRT-
15Z 15 days after completing SBRT; SBRT-40Z 40 days
after completing SBRT.
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reported Expanded Prostate Cancer Index Composite
(EPIC)-based QoL after prostate intensity modulated RT,
brachytherapy, or surgery. That study, which followed pa-
tients for up to 2 years after treatment, showed patterns of
urinary and bowel decline in scores after EBRT of a
magnitude range of 10 to 15 EPIC score points, occurring
at approximately 2 months posttreatment and returning to
baseline scores at approximately 6 months. Our analysis
after extreme hypofractionated treatment showed increases
of 2.7 and 7 PR-25 points in GI and GU symptoms at
3 months posttherapy, respectively.
Regarding the sexual QoL domain, the study by Sanda
et al showed a decline of approximately 10 EPIC score
points, peaking at around 2 months.5 This outcome is in
striking contrast to our study, where we observed a decrease
of only 4 score points at 3 months. Although we
acknowledge that sexual dysfunction may increase with
longer follow-up, the differences observed between our
study and the one reported by Sanda et al may exist, in part,
because most of our patients refused to undergo ADT,
which generally causes immediate and long-term sexual
dysfunction.
Although ADT was recommended to all, most of our
patients declined to undergo this treatment. This outcome
could be the result of a cognitive bias because most patients
declined standard ADT in the hopes that experimental,
higher-dose radiation to the prostate could provide equal
disease control with better QoL, and especially sexual QoL,
compared with the addition of ADT. King et al did not
reveal any benefit from ADT, either in local or systemic
control, when given during SBRT in intermediate-risk and
high-risk groups.7 Despite the strong level-1 scientific ev-
idence supporting the use of ADT with conventional EBRT
in intermediate- and high-risk patients, a recent systemic
review reported that only 27.8% of the patients treated in
the context of prostate dose escalation received ADT.48
According to the current evidence, it is difficult to rule
out that dose escalation to the DIN could provide a benefit
for local tumor control in the same magnitude as the
addition of ADT. Certainly the lack of use of ADT in our
study limits generalizability of our results because ac-
cording to the standard approach, these patients should
have all received ADT.
Because of the small number of patients included and
the short patient follow-up (median, 24 months), we were
not able to reliably evaluate the biochemical outcome.
Therefore, the early PSA kinetics provided in Figure E1
(available online at https://doi.org/10.1016/j.ijrobp.2018.
09.023) should be interpreted with caution. Mature pros-
tate SBRT trials have been summarized in a recent re-
view.48 Most SBRT trials have focused on patients with
low- to intermediate-risk disease, with limited experience
in higher-risk patients. King et al performed a combined
analysis of 1100 patients treated in SBRT trials to 35 to
40 Gy in 4 to 5 fractions. Thirty percent had intermediate-
risk disease (median follow-up, 30.5 months), and 11% hadhigh-risk disease (median follow-up, 23 months).
Biochemical control for intermediate-risk and high-risk
patients was 84% and 81%, respectively.7 Katz reported
10-year biochemical control of 93% for low-risk patients
who received 35 to 36.25 Gy in 5 daily fractions.49
A Canadian trial recently reported 5-year biochemical
control rate of 97% in patients at low-to intermediate risk
who were treated with 40 Gy in 5 fractions delivered over
29 days (once-a-week treatment).50 This biochemical con-
trol rate was comparable to that of studies using 40 to
50 Gy in 5 fractions delivered every other day14,45,51 and
showed better tolerability.44
Longer follow-up will be needed in our study to see if
the early PSA kinetics obtained in this population of in-
termediate- and high-risk patients translates into lower
biochemical failure rates. Therefore, biochemical outcome
and long-term toxicity will be reported after all patients in
the ongoing phase 2 study have been followed for a mini-
mum of 5 years.
Phase 3 randomized trials are now underway to directly
compare prostate SBRT versus conventional and moder-
ately hypofractionated RT. They include HYPO-RT-PC
(78 Gy/39 fractions vs 42.7 Gy/7 fractions,
ISRCTN4590532), PACE-A (radical prostatectomy vs
36.25 Gy/5 fractions, NCT01584258), PACE-B (78 Gy/39
fractions or 62 Gy/20 fractions vs 36.25 Gy/5 fractions,
NCT01584258), HEAT (36.25 Gy/5 fractions vs 70.2 Gy/
26 fractions, NCT01794403), and NRG GU005 (36.25 Gy/
5 fractions vs 70 Gy/28 fractions, NCT03367702). We
believe our study provides further evidence to develop
clinical trials aimed at optimizing SBRT for patients with
high-risk disease who may require doses higher than those
currently reported in the literature.
The abscopal effect of local RT has been shown to be T-
cell mediated and antigen specific and indicates that tumor-
associated antigens specific to T-cell activation can take
place during an ongoing radiation treatment.16 However,
EBRT also has negative effects on lymphoid cells. Lym-
phopenia often occurs after local RT, as observed in pros-
tate, testicular, and gynecologic cancers.52-55 Pioneering
work by Tabi et al showed decreased circulating lympho-
cyte numbers in the blood after pelvis RT (55 Gy in 20
fractions to the prostate, 2.75 Gy per fraction; and 44 Gy in
20 fractions to pelvic nodes, 2.2 Gy per fraction).56 The
reduction in lymphocyte numbers was observed 4 weeks
after completing pelvis RT and affected mainly the T-cell
population, which also showed decreased IFN-g produc-
tion.56 We were unable to observe lymphopenia in our
patients. Our hypofractionated treatment plans incorporated
a significantly smaller PTV than the one reported by Tabi
et al,56 who also included elective nodal irradiation. Thus,
the smaller PTV could explain the absence of
lymphopenia.56
Previous comprehensive translational research by Nes-
slinger et al showed antibody responses against shared PCa
antigens in 14% of patients undergoing standard pelvis and
prostate RT and in 20% of patients undergoing prostate
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of HLA-A2erestricted, surviving peptide
(LMLGEFLKL)especific, tetramer-positive T cells in pa-
tients with PCa who were undergoing standard RT.
Increased tetramer-positive CD8þ T-cell frequencies were
observed in 1 of 10 patients (10%) during RT and in 2 of 7
patients (28%) after RT.58 We found evidence of immune
recognition of prostate cancer tumor-associated antigens at
baseline in many patients, which may explain why immu-
notherapy approaches have shown some promise in the
management of recurrent forms of PCa, especially when
administered in conjunction with interventions that can
mitigate immunologic tolerance or with vaccines that in-
crease antigen availability.53,59,60 We show for the first time
that SBRT overall enhanced such antigen-specific T-cell
responses in patients where such responses were detected
also at baseline (ie, 5 of 8 HLA-A2þ patients evaluated).
Given the small number of patients, our study does not
allow us to ascertain whether radiation-induced antibody
response has an important antitumor effect. Interestingly,
the in situ vaccination effect of RT persisted also at the 40-
day follow-up period, suggesting that RT-induced immune
activation may be persistent for a while, thus creating a
window of opportunity for combinations with immuno-
therapy drugs. In future trials, the ideal partners for SBRT
should be monoclonal antibodies that boost the in situ
vaccination effect through antigen-presenting cell stimula-
tion (OX40 agonists, CD40 agonists, toll-like receptor ag-
onists, CD137 agonists, CTLA-4 inhibitors, or vaccines).16
In addition to direct antigen-presenting cell activation,
additional immunotherapy interventions that simulta-
neously sustain the effector capacity of T cells could be
very useful in combination with SBRT (PD1 and PDL1
inhibitors).16
Several limitations of our study are acknowledged. The
sample size is too small to derive any definitive conclu-
sions. The follow-up time is too short to assess biochemical
outcome, QoL, and long-term toxicity, but these outcomes
will be reported after the ongoing phase 2 study has reached
maturity. An additional limitation is that the number of
patients included in the translational study was limited by
the selection of patients with HLA-A2. Because HLA al-
leles are highly polymorphic, we focused our efforts on the
HLA-A2 population, which is the most frequent HLA allele
in the white population, and most presently known PCa
specific T-cells epitopes are HLA-A2 restricted. Therefore,
only 40% of our patients were eligible to participate in the
translational research.
In the future, we plan to approach this problem by
incorporating cancer genome sequencing in tumor biopsies
to enable rapid identification of private nonsynonymous
mutations. This can be done through a single nucleotide
mutation that results in changes of the amino acid sequence
of a protein, expressed at different frequencies in a patient’s
tumor, that can be used as personalized immunogens.
Predictive algorithms for major histocompatibility class I
binding, which choose epitopes on the basis of predictedaffinity, will provide a rapid and unbiased approach to
epitope prioritization. Neoantigens induced upon tumor cell
death provoked by SBRT may be included in a personalized
tumor vaccine that could be combined with immuno-
therapy, ADT, or both in this category of patients.
Furthermore, because of the limited number of patients and
because we applied a gold standard (highly sensitive
antigen-screening assays), we believe that our data need to
be reproduced in a larger cohort of patients using the same
assay to confirm our observations. We thus acknowledge
that the work presented in this article is preliminary, but it
opens the door for more translational research in PCa, a
disease that is poorly responsive to immunotherapy.Conclusions
Dose escalation to the DIN in this phase 1 trial was possible
up to 50 Gy delivered in 5 fractions. The early PSA kinetics
were considered promising, whereas the preliminary QoL
analysis showed a favorable profile. This outcome was
likely a result of the significant efforts made to spare
healthy tissues from high doses of radiation. Because no
DLT was observed and the MTD was not reached, we are
currently enrolling patients into the phase 2 part of this
study that uses the 50-Gy dose level. This extreme hypo-
fractionated regimen enhanced antigen-specific immune
recognition in a subset of patients. Therefore, immunologic
mechanisms may contribute to clinical outcomes after
SBRT, an effect that could potentially be exploited with
immune-activation approaches, including checkpoint
blockade and vaccination.References
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